首页> 外文期刊>Clinical ophthalmology >Short-Term Non-Infectious Outcomes After a Pars Plana Intravitreal Antibiotic-Steroid Injection of Triamcinolone, Moxifloxacin, and Vancomycin During Cataract Surgery versus a Standard Postoperative Topical Regimen
【24h】

Short-Term Non-Infectious Outcomes After a Pars Plana Intravitreal Antibiotic-Steroid Injection of Triamcinolone, Moxifloxacin, and Vancomycin During Cataract Surgery versus a Standard Postoperative Topical Regimen

机译:在白内障手术期间,在白内障手术期间,术治疗术治疗术治疗术治疗术后术后局部方案

获取原文
获取外文期刊封面目录资料

摘要

Purpose: To compare short-term non-infectious clinical outcomes after cataract surgery with an intraoperative pars plana intravitreal antibiotic-steroid (IVAS) injection of triamcinolone, moxifloxacin, and vancomycin (TMV) versus a standard postoperative topical regimen. Patients and Methods: A retrospective comparative case series of 1058 eyes (control = 487, treatment = 571) undergoing cataract surgery?were included. Endpoints included best-corrected visual acuity (BCVA), intraocular pressure (IOP), and the unplanned use of anti-inflammatory topical medication in the postoperative period. The follow-up period ranged from 1 to 6 months. Results: A final monocular BCVA of 20/25 or better was achieved in 78.8% and 87.4% of eyes in the control and treatment groups, respectively (p = 0.001). The overall incidence of an IOP spike (Δ ≥ 10 mm Hg) was not significantly different between the two groups (0.4% versus 1.9%, p = 0.027). The rates of persistent anterior chamber inflammation (PACI), rebound anterior chamber inflammation (RACI), and cystoid macular edema (CME) in the control and treatment groups were 8.0% vs 2.6% (p 0.001), 6.4% vs 2.6% (p = 0.003), and 3.9% vs 4.7% (p = 0.511), respectively. The use of an IVAS injection of TMV conferred an increased risk of CME (odds ratio [OR] = 3.21, 95% confidence interval [CI] = 1.42 to 7.23) but no significant effect on the risk of PACI (OR = 0.34, 95% CI = 0.10 to 1.14) or RACI (OR = 0.52, 95% CI = 0.18 to 1.54) when compared to a topical regimen. Conclusion: An intraoperative IVAS injection after uncomplicated cataract surgery may be as safe and effective as a standard topical regimen in terms of postoperative IOP and anterior chamber inflammatory events, respectively. However, the efficacy of a TMV formulation for CME prophylaxis appears to be unsatisfactory. Future studies with prospective and randomized designs are needed to further evaluate this technique.
机译:目的:在白内障手术后与术中para术治疗术治疗术术术治疗术术,莫西葡萄酒和万古霉素(TMV)与标准术后局部方案进行比较术中的短期非传染性临床结果。患者及方法:介绍了1058只眼(Control = 487,治疗= 571)的回顾性比较案例系列?包括在进行白内障手术中?终点包括最佳校正的视力(BCVA),眼内压(IOP),以及在术后期间的抗炎局部药物的意外使用。随访期限为1至6个月。结果:分别在对照和治疗组中的78.8%和87.4%的眼睛中实现了20/25或更好的最终单像素BCVA(P = 0.001)。两组(0.4%对1.9%,P = 0.027)之间的IOP穗(δ≥10mmHg)的总发动率没有显着差异。对照和治疗组中持续前室炎症(PACI),反弹前室炎症(RACI)和囊状黄斑水肿(CME)的速率为8.0%Vs 2.6%(P <0.001),6.4%Vs 2.6%( P = 0.003),分别为3.9%Vs 4.7%(p = 0.511)。使用IVAS注射TMV的CME风险增加(差距[或] = 3.21,95%置信区间[CI] = 1.42至7.23),但对PACI的风险没有显着影响(或= 0.34,95与局部方案相比,%CI = 0.10至1.14)或raci(或= 0.52,95%CI = 0.18至1.54)。结论:在不复杂的白内障手术后的术中注射可能是术后IOP和前腔炎症事件的标准局部方案。然而,TMV制剂对CME预防的效果似乎是不令人满意的。需要使用前瞻性和随机设计的未来研究来进一步评估这种技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号